Pressure BioSciences PBIO OTC and Master Distributor Canopy CBD Farms Announce Major Increase in UltraShear Nanoemulsion Platform Pipeline- Should You Buy Now !

Rapid Q3/Q4 2023 Sales Growth Forecasted from North American Cannabis Retailers and Wholesalers

SOUTH EASTON, MA / ACCESSWIRE / July 26, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, biotherapeutics, food/beverage, and other industries, announced today that Canopy CBD Farms LLC (“CCF”), the Company’s Master Distributor for Cannabis Products in North America, has reported a significant increase in the pipeline of retailers and wholesalers engaged in negotiations for PBIO’s UltraShear-processed nanoemulsions of CBD, THC, and other cannabinoids. One week ago, the Company entered the rapid expansion phase of its UltraShear Nano-CBD commercialization program (Phase 2). Working with the Company, CCF increased its short-term pipeline to over a dozen companies with strong interest in contracting for access to UltraShear nanoemulsified hemp and cannabis-derived products. CCF expects that half of these companies will generate purchase orders for UltraShear products/services over the next two weeks; the rest are expected to contract for UltraShear-processed products in a month.

Mr. John Westlake, President of CCF, emphatically stated: “There is a high level of excitement and interest in UltraShear-processed CBD nanoemulsions derived from hemp. Many customers now understand the clear advantages of the UltraShear platform and have been anxiously awaiting the transition to Phase 2, which would allow them to order UltraShear processed products. We believe the dozen companies added this week to our contracts pipeline are just the tip of the iceberg. We also believe that our contracts pipeline number will grow significantly as we transition further into commercialization Phase 2.”

Mr. Westlake continued: “CCF is proud to announce that one of the most respected Key Opinion Leaders in the cannabis industry, John MacKay, Ph.D., has agreed to support CCF in a technical role. Dr. MacKay’s experience and expertise is invaluable. He will help drive the adoption of the UltraShear platform through solid science and strong business acumen. We are honored to partner with Dr. MacKay as we pioneer the UltraShear platform release to the growing cannabis industry.”

As the founder and CEO of Synergistic Technologies Associates, Dr. MacKay will leverage his more than 40 years of commercial and academic expertise to advance acceptance of the UltraShear platform in the cannabis industry. Dr. MacKay’s perspective coupled with his extraction, separation, and formulation expertise will be valuable to all of PBIO and CCF’s prospective cannabis industry business partners, ultimately benefiting the end users of UltraShear nanoemulsified cannabinoids. John MacKay (thecannabisscientist.com).

Six of the more exciting examples of opportunities being developed and negotiated by CCF are highlighted below, with deal closures expected over the coming days and weeks:

• Research agreement with highly-respected MA company to evaluate quality of THC and CBD nanoemulsions.
• Standing order for white label CBD spray bottles with a renowned Massachusetts dispensary.
• Formulation agreement with specialty manufacturer and distributor of premium Phyto cannabinoid ingredients.
• Product formulation and white label bottle contract with a well-known, hemp-based, global products cGMP manufacturer in the Mountain Region of the U.S.
• Formulation and nanoemulsion ingredients supply to a Massachusetts-based cannabis beverage manufacturer.
• White label contract with a large, mid-west, MS operator to market and sell PBI’s unique Nano-CBD topical spray.

Mr. Richard T. Schumacher, President and CEO of PBIO, stated, “We are encouraged by the results from our partner CCF in their recent aggressive marketing of the UltraShear platform to new geographical areas and companies. It is exciting to see the expanding interest generated, which we believe will manifest itself in rapidly increasing revenue in Q3/Q4 2023.”

Mr. Schumacher concluded: “With recent advances in our technology base, and in our current UltraShear commercialization roll-out, we believe PBIO’s future has never been brighter. We are highly disappointed in the Company’s stock price, which we believe in no way reflects PBIO’s present worth nor its future potential. As evidence of management’s faith in PBIO’s future, Jeff Peterson (Chairman) and I have committed a large part of our personal net worth to PBIO. As evidence of our staff’s faith in PBIO’s future, and upon the request of multiple employees, efforts are being made to institute an employee stock purchase plan to facilitate share acquisition by the staff. During my professional career, I have priorly founded/co-founded three successful public companies, yet in my opinion, none had close to the potential that we now have in PBIO.”

About the Upcoming Cannabis Drinks Expos in San Francisco and Chicago

Additional lead generation and UltraShear brand awareness activities will be generated at the upcoming Cannabis Drinks Expos in San Francisco on July 27^th and in Chicago on August 1^st. PBIO and CCF staff will attend both meetings.

About Canopy CBD Farms LLC

Manufacturer of compliant commercial industrial hemp outputs. Led by a United States Air Force veteran and experienced entrepreneur with a demonstrated history of working and networking in cannabis. Strong knowledge in cultivation, processing, manufacturing, and business development. Specializing in contract manufacturing with established companies, producing ready to formulate CBD, and minor’s solutions. Utilizing UltraShear Technologies to use in CBD/THC beverages & edible products. CCF is combining skills and services with Dr. John MacKay, an internationally recognized scientific expert in analytical testing, extraction, and purification techniques within botanical space. His career has included many roles in innovative product development. Dr. MacKay is currently a contributing journalist of Extraction Magazine, a cannabis extraction publication, and Terpenes and Testing Magazine, a publication serving the cannabis industry with cannabis news and science on horticulture, extraction, and testing labs.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

Scientific Publications Demonstrate Effectiveness of CBD and Essential Oil Nanoemulsions in Shelf-Life Extension of Fruits and Vegetables; PBI Initiating Studies with Industrially Scalable UltraShear Nano-CBD

SOUTH EASTON, MA / ACCESSWIRE / July 25, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide food and beverage, agrochemicals, nutraceuticals, cosmeceuticals, biotherapeutics, and other industries, announced today the initiation of studies to evaluate and demonstrate its industrially-scalable UltraShear Technology™ (“UltraShear™”) platform for producing oil-in-water nanoemulsions in the preparation of edible coatings of Nano-CBD to extend the shelf life and preserve the quality of fruits and vegetables.

Edible coatings are commonly used to enhance the quality and increase the shelf life of fruits and vegetables. However, industrial-scale use of edible coatings has struggled with effectiveness limitations due to poor stability and solubility of the coatings. Recent developments in nanoemulsion-based coating technology offer promise for an effective and efficient strategy but have been challenged by industrial-scaling limitations as well as quality and stability inconsistencies from current nanoemulsion technology platforms. The extremely low and consistent nano-droplet size distributions and stability achieved by PBIO’s UltraShear platform, and its easy process scalability, offer exciting promise as a preferred platform for delivering and standardizing these innovative quality and preservation solutions for produce.

Cannabidiol (“CBD”), the primary non-psychotropic ingredient in cannabis or hemp plants, is now approved by the FDA for the treatment of seizure conditions. CBD has enjoyed much wider use for treatment of pain and disorders from ~4000 BCE in China to its rapidly widening modern popularity in treating pain, anxiety, sleep disorders and much more. For over two decades, studies have demonstrated CBD’s antimicrobial effectiveness against human pathogens and more recently against plant pathogens (especially fungi associated with rot development in produce). These studies are now generating great interest among consumers increasingly focused on all natural and organic, preservative-free, “green-label” foods, and for investors focused on solutions for the enormous agricultural industry segment.

A recent peer-reviewed article (“Influence of a Transparent and Edible Coating of Encapsulated Cannabidiol Nanoparticles on the Quality and Shelf Life of Strawberries”) published on May 4, 2023 in the American Chemical Society (ACS) Journal of Applied Materials and Interfaces focused on the antimicrobial activity of strawberries coated with CBD-infused nanoparticles. The article reported on the results of treated/untreated strawberries, showing that the CBD-treated samples ripened and decayed much more slowly than the untreated ones. Other scientific articles with similar results on nanoemulsified CBD, essential oils, and other natural additives have also been recently published advanced edible coatings.

Mr. John Hollister, Director of Marketing and Sales for PBIO, noted: “We are now awaiting the publication in a scientific peer-reviewed journal of recent research performed by a leading global cannabis academic research team contrasting the vastly superior absorption and bioavailability of PBIO’s UltraShear Nano-CBD versus the routinely reported oral-GI absorption of current CBD formulations. In light of these results, we are now embarking on studies of UltraShear Nano-CBD as an optimal effective strategy for a new generation of all-natural, edible food coatings.”

Mr. Richard T. Schumacher, PBIO’s President and CEO, concluded: “We have been delighted by recent inquiries from investors and food processing groups, who recognize our UltraShear platform as the preferred, best-in-class solution for the development of the highest quality, industrially-scalable, and long-term stable nanoemulsions of CBD and essential oils.”

Mr. Schumacher continued: “We are excited about our obvious prospects for a leadership role in this important and growing applications area. Of course, this is only one of a myriad number of major market opportunities for our UltraShear platform, spanning nutraceuticals, cosmeceuticals, agrochemicals, pharmaceuticals, and the food/beverage sectors. Our UltraShear Nano-CBD is already fully formulated, soundly tested, recently launched into human topical and soon oral applications, and is ready for prime time!”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

During Interview with “Cannabis Talks” (Cannabis and Hemp Insider), CEO Ric Schumacher Reveals Transition into Aggressive Growth Phase for Revolutionary Nano-CBD with U.S. Retailers and Wholesalers

SOUTH EASTON, MA / ACCESSWIRE / July 17, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, biotherapeutics, food and beverage, and other industries, announced today in an interview with renowned cannabis business authority Jeffrey Friedland that PBIO was now advancing into Phase 2 of commercialization of its revolutionarily-effective, UltraShear™-processed nanoemulsified CBD topical spray, transitioning from early, targeted sales and marketing efforts into rapid expansion plans for its nationwide and global distribution base.

Jeffrey Friedland, the CEO of FC Global Strategies and a thought-leader in the cannabis, hemp and CBD industries, is an author quoted in publications including the Wall Street Journal, New York Times, USA Today, Forbes, Bloomberg TV, NBC.com, and other leading business periodicals, a sought-after speaker at conferences globally, and is the host of online interview programs including “Business Connect Insider,” “Medical and Pharma Insider,” “Emerging Technology Insider” and “Cannabis and Hemp Insider.” Click here to hear Mr. Friedland’s interview with PBIO’s President and CEO, Mr. Richard T. Schumacher: PBIO Video Interview July 16, 2023

Mr. Schumacher explained in the interview: “There has been significant noise in the CBD and broader cannabis markets from companies touting a nanoemulsion offering in the past few years, but none are able to match UltraShear’s capability to deliver tightly controlled nano-droplet sizes in the sub-100 nm range, with rock-solid stability, easily and affordable scaled-up production efficiency, and elimination of the metal contamination resulting from the most commonly-used competitive technology today. We initially hand-picked a small, select group of retailers for our first round of efforts in the sale and distribution of our Nano-CBD Topical Spray product, which allowed us to explore and optimize factors like product formulation, CBD concentration targets, bottle and dispenser technology, product size and packaging configuration, pricing, and shipping logistics. This first phase of activity was extremely productive in answering those questions. We now have a confidently-designed product and an accumulation of powerful UltraShear Nano-CBD Topical Spray user testimonials.”

Mr. Schumacher continued: “Effective this week, we enter PBIO’s Phase 2 of our Nano-CBD commercialization strategy with rapidly expanding efforts to welcome and integrate many additional retailers and wholesalers across the USA, while we introduce and establish our uniquely fast-acting and potent Nano-CBD topical spray to the broader U.S. and global markets. As we have mentioned in recent news releases, independent research by a leading cannabis academic team has dramatically confirmed our UltraShear-processed Nano-CBD product to have uniquely differentiated performance over all existing known CBD products (compared to the gold standard of IV infusion), and we anticipate the release of those results in a peer-reviewed scientific journal in the near future.”

Pressed by Mr. Friedman to discuss the expected impact of this announced Phase 2 upon PBIO’s business results for the remainder of 2023 and beyond, Mr. Schumacher concluded: “We anticipate signing up over 20 retailers and wholesalers in the remainder of 2023, with an estimated incremental revenue impact of $2-3 million over 2022 results. We also plan to launch our UltraShear Nano-CBD Oral Spray product this October. Over the next 12 months, our goal is to sign and launch at least 50 new UltraShear Nano-CBD retailers and wholesalers, and to achieve at least $10M in incremental revenue impact in 2024. This is a very exciting transition time for our team, our investors, and for the world of CBD and cannabis users!”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilizeboth constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly.

PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

Somalab to Enhance Existing and New Products with PBIO’s UltraShear Platform.

Somalab to Immediately Begin Distribution of PBIO’s Best-in-Class Nano-CBD Topical Spray.

Companies to Collaborate on Development & Sale of Novel, UltraShear-Enhanced Brain Boost Supplement.

SOUTH EASTON, MA / ACCESSWIRE / July 5, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, biotherapeutics, food and beverage, and other industries, and Somalab International LLC (“Somalab”), a Texas-based leading supplier of novel health and wellness products throughout the U.S., today announced the execution of an agreement (the “Agreement”) for the collaborative development and distribution of UltraShear™ Technology (UltraShear™)-enhanced health and wellness products.

Under the Agreement, the companies will (i) use the UltraShear platform to increase the already high quality of existing Somalab products to even higher, next-generation levels; and (ii) collaborate to develop new products that offer this same next-generation level of quality, including an enhanced “Brain Boost” product. Somalab will also immediately begin distribution of PBIO’s best-in-class, preservative-free, 100% plant-based, and highly bioavailable Nano-CBD topical spray.

Mr. Earl Green, CEO and Founder of Somalab, commented: “In our never-ending pursuit of excellence, we recently discovered PBIO and their UltraShear technology. We quickly learned how and why their patented UltraShear platform delivers the best-in-class nanoemulsification solution available worldwide. We are thrilled to begin the announced collaboration, which will include enhancements to several of our products that already provide leading quality performance levels, as well as the introduction of their unique Nano-CBD topical spray to the thousands of customers in our data base.”

Mr. Green continued: “We are also very excited about collaborating with PBIO on the development of a next-generation Brain Boost product. Our current Brain Boost Caps are one of our best sellers. But even a “best seller’ can be enhanced, which we fully expect from the nanoemulsions resulting from UltraShear processing. Brain health is very important, but it can be hard to recover and/or maintain as we grow older. Fortunately for our customers, we believe that UltraShear processed nanoemulsions will enhance our already powerful and effective Brain Boost products.”

Mr. Richard T. Schumacher, PBIO’s President and CEO, commented: “This is a tremendous opportunity for both companies. Somalab benefits with immediate sales from PBIO’s preservative-free, all plant-based, highly bioavailable, and best-in-class Nano-CBD topical spray. PBIO benefits from significant incremental revenues expected from these sales. Both companies benefit by incorporating UltraShear processing into Somalab’s existing and future product line.”

Mr. Schumacher added: “We believe Somalab’s sale of our Nano-CBD will add over $200,000 in revenue for PBIO in 2023 and more than $1,000,000 in 2024. As exciting as that forecast is, we believe sales of an UltraShear-based, next-generation Brain Boost product could easily eclipse sales of Nano-CBD during 2024 – and Somalab is already suggesting additional products that could exceed our forecast for the UltraShear-enhanced next-generation Brain Boost product.”

Mr. Schumacher concluded: “In addition to announcing this very exciting and profitable partnership with Somalab, we have also recently closed on several additional business transactions that will be announced in the coming days – transactions that we believe will also have significant impacts on our sales and growth during the second half of 2023, and beyond.”

About Earl Green

At age 17, shortly after his best friend died in an auto accident, Earl suddenly began to experience seizures. Over time, the seizures became more frequent and intense. Doctors eventually prescribed the maximum dose of Keppra, but the medication caused drastic side effects. He became irrational, aggressive, angry, depressed, even suicidal, and he gained almost 70 pounds. Mental clarity became foggy and academic work that was once easy became difficult. Every seizure lost Earl a month or more of memory. Two years after his first seizure, Earl discovered the therapeutic potential of cannabinoids and CBD in particular. He began to take cannabinoid supplements with his seizure medication, experienced great success with seizure relief, and was eventually taken off Keppra entirely. He attended college and earned a bachelor’s degree in sustainable development engineering with a specialty in pharmaceutical administration. He founded Somalab in 2017.

About Somalab International LLC

Somalab (www.somalab.us) was founded on principles of natural wellness and empathy towards the health struggles of every individual and is dedicated to seeking and recognizing natural opportunities for synergy and innovation. In the development and on-going maintenance of products, Somalab is scientifically driven and performs research, tests, and studies new ways to innovate to increase quality and to continuously improve the effectiveness of their products.

25 Consumers Affirm UltraShear Nano-THC Spray Produces Desired Fast Initial and Max Effects,
No Lung/Health Concerns from Smoke/Vape, and No Delayed and/or Impatient Excess Dosing from Edibles

REMINDER: Webinar Focused on the Company’s Revolutionary UltraShear Platform Today at 4:30PM EST

SOUTH EASTON, MA / ACCESSWIRE / June 27, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or “Company”) today announced results from a third round of consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks and under the tongue. The Nano-THC Oral Spray was prepared using PBI’s revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI’s California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products.

An additional 25 consumers recently participated in this on-going focus group testing, bringing the total to over 60 participants to date. Once again, the respondents strongly affirmed key attributes that powerfully differentiate UltraShear processed Nano-THC Oral Spray from the participants previous edible THC experiences, with major emphasis on:

1. Speedy onset of first effects (average well under ten minutes, with many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes for initial onset.
2. Much faster progression to maximum effects (average well under 30 minutes, with many reports in 20 minutes or less) versus typical THC edibles requiring 60-120 minutes.
3. Elimination of health issues associated with smoking or vaping.
4. Efficiency improvements in dose payload delivery, with many reporting equal or better/greater THC experience from dosing at a fraction of user’s normal dosing levels.
5. Stable, all plant formulation is sterile packaged with no added preservatives.
6. Multiple consumers applied a single spray to painful body areas and reported fast to instant transdermal pain relief.
7. Multiple consumers with difficulty in falling asleep detailed how they quickly fell asleep and remained asleep through the night.

Mr. John B. Hollister, PBIO’s Director of Sales and Marketing, shared highlights from the three studies: “We continue to be thrilled by the feedback we are receiving from study participants. It confirms our belief that UltraShear is not just the next interesting/better mousetrap – but that it should drive a real paradigm shift and sea change in how a great many cannabis products will be consumed in the future. The nanoemulsions that we are creating for cannabinoids and many other product areas are clearly meeting and fulfilling the challenge of fast, efficient, and effective delivery of historically difficult to absorb oil-soluble active nutrients and therapeutics that all who came before us failed to achieve.”

Mr. Hollister continued: “The growing and often unsolicited feedback we are receiving about the potential of these UltraShear nanoemulsified products is very encouraging. One of the study respondents, “AE”, asked whether he could spray some on his side where he had strained and injured some muscles in a ski accident, and the pain was seriously impacting his mobility. Within five minutes of four quick sprays on the area, he looked over and said, “This is amazing. I can move again.” While THC and CBD are known for pain relief effectiveness, it was shocking to witness the difference in that short amount of time – and we have now received numerous stories of these and even faster experiences.”

Mr. Richard T. Schumacher, President and CEO of PBIO, summarized: “These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market. We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential for explosive adoption of UltraShear processed Nano-THC.”

Mr. Schumacher continued: “We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage, and more. The second half of 2023 is poised to be a watershed transformational time for PBI, as we capitalize on the roll-out of the UltraShear platform, not just in cannabis, but across other major consumer-driven markets as well.”

About Today’s UltraShear Platform Webinar

The Company’s President and CEO, Mr. Richard T. Schumacher, is the featured speaker at an online webinar scheduled for Tuesday, June 27, 2023, at 4:30 PM EST. The webinar is entitled: “From Concepts to Success: Pressure BioSciences UltraShear™ Platform Revolutionizing Cannabis, Nutraceuticals, Cosmeceuticals, and Multiple Other Industries.” During this webinar, participants can expect to gain a quick overview of Pressure BioSciences Inc. (OTCQB: PBIO) and its core technologies and products, as well as learn about the Company’s powerful UltraShear Technology platform and its transformative impact on various industries. A Q&A session will follow the formal presentation. Register here to secure your spot: PBIO Webinar Registration 6.27.23

VST Mission is to Serve Current and Past Members of US Armed Services and Coast Guard Through World-Class, Highly Effective, and Natural Wellness Products that Benefit the Mind, Body, and Soul

SOUTH EASTON, MA / ACCESSWIRE / June 13, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the global nutraceuticals, biotherapeutics, cosmeceuticals, agrochemical, and food/beverage industries, among others, and the Veterans Service Team (“VST”) (www.vst.org), a self-funded, 501(c)3 non-profit company dedicated to the support and wellness of active duty and former members of all branches of the US Military and US Coast Guard, today announced a long-term (5-year) development and supply agreement between the companies.

PBIO’s Ultra Shear Technology™ (UltraShear™ or UST™) platform allows oil-soluble active molecules like CBD to be prepared into nanoemulsions of vanishingly tiny oil droplets in water that ensures rapid absorption and unparalleled bioavailability of the CBD (or other active ingredients) into the water-based biochemistry of human bodies. The PBIO-VST partnership offers VST membership exclusive access to custom-designed, hemp-derived, UltraShear-processed nanoemulsions of CBD oil in water (“Nano-CBD”), providing unparalleled speed of action and reliable dosage delivery. As new UltraShear-processed nanoemulsified wellness, beauty, and nutraceutical products are developed and become available, these too will be readily offered to VST members, some of them also on an exclusive basis.

Mr. Howard Zall, COO of VST, commented: “Our mission is to serve the roughly 18 million current members and veterans of the US Armed Services and Coast Guard with education, support services, and a potent collection of diverse, carefully selected wellness products. We are in the early stages of building our membership, through which we expect to increase VST to over 2 million members in the next five years. It is our sincere honor to serve our Nation’s Heroes.”

Mr. Zall continued: “A leading-quality CBD product with world class speed and completeness of effectiveness has been the most important new offering that we have been targeting for our growing VST member base in 2023, to help address and manage their diverse, critical needs. Following extensive due diligence, we determined PBIO’s UltraShear Technology was the world’s leading platform for developing highly effective nanoemulsions of CBD in either a topical or oral spray. For VST, both formulations will be custom-developed and packaged by PBIO. In addition to being preservative-free, plant-based, all natural, fast-acting, highly bioavailable, and extremely potent CBD products, the products will be configured with unique features only available to VST members. We are very excited to partner with PBIO, and to soon introduce to our membership our first collaborative product: a revolutionary, one-of-a-kind, nanoemulsified CBD topical spray.”

Captain George Ackerson, CEO and Founder of VST, and a two-tour veteran – Vietnam (circa 1971) as a Warrant Officer special operations scout helicopter pilot, and (circa 1978) as a Commissioned Officer in aviation maintenance and attack helicopter test pilot, stated: “Initially, we will be launching our custom-designed, one-of-a kind, UltraShear Nano-CBD Topical Spray, with its sister product (UltraShear Nano-CBD Oral Spray) to quickly follow. These unique products, to be available exclusively to VST members only, will be superbly targeted to address large and important unmet needs within the U.S. active military and veteran’s communities. Results to date have demonstrated PBIO’s UltraShear nanoemulsion processing capabilities go far beyond other so-called nano products currently on the market – with performance significantly better than we could have ever dreamed. We are very proud to partner with the amazing innovation team at PBIO.”

Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: “We at PBIO have tremendous respect for George, his Team, and the VST mission. One-hundred percent of all VST efforts support current and past members of the US Armed Services and Coast Guard; in addition, VST donates 100% of its profits to veteran’s charities and to Animal ‘Rescue’ Shelters across the US. We are truly honored to announce this partnership and to provide the VST membership with a new, unique line of UltraShear nanoemulsified CBD products, as well as other wellness, beauty, and nutraceutical products in the future.”

Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: “With VST’s membership expected to exceed 2 million of the nearly 18 million active-duty personnel and veterans within five years, PBIO and VST are estimating PBIO’s incremental revenue from this relationship will grow significantly year-over-year, from initial annual revenue of about $1.5M to revenue topping $15M in the fifth year of the agreement. These projections are for Nano-CBD products sales only, which the companies believe will be generated from sales of up to 50,000 spray bottles in Year 1 to approximately 500,000 spray bottles in Year 5. PBIO investors and VST members can expect to hear much more about additional UltraShear processed products offered through VST in the weeks and months ahead.”

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

NEW YORK, June 12, 2023 (GLOBE NEWSWIRE) — FMW Media’s New to The Street , a nationally syndicated TV show, announces episode 478 airing on the Fox Business Network , tonight Monday, June 12, 2023, at 10:30 PM PT.

New to The Street’s 478th TV episode line-up, features the following Five (5) Corporate interviews:

1). Women’s Healthcare – Aspira Women’s Health (NASDAQ: AWH) ($AWH) interview with Nicole Sandford, President, CEO, and Board Member, and Dr. Ryan Phan, Ph.D., Chief Scientific, and Chief Operating Officer .

2). American Made Products – American Rebel Holdings, Inc.’s (NASDAQ: AREB) ($AREB) interview with Andy Ross, Chairman and CEO.

3). Investor Marketplace – Blue Castle Ventures Ltd.’s (CRYPTO: BCVD) ($BCVD) interviews with David Rojas, CEO/Founder .

4). Life Sciences Industry Equipment – Pressure BioSciences, Inc.’s (OTCQB: PBIO) ($PBIO) interview with Richard T. Schumacher, President/CEO.

5). ” Sekur Privacy & Sekur Security Segment – The Weekly Hack ” interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) ( Sekur® ).

Episode 478

On tonight’s show, Nicole Sandford, President, CEO, and Board Member, and Dr. Ryan Phan, Ph.D., Chief Scientific Officer, and Chief Operating Officer of Aspira Women’s Health (NASDAQ: AWH) ($AWH) are at the Nasdaq MarketSite studio talking with New to The Street’s TV Host Jane King. The Company focuses on women’s reproductive health and other gynecologic disorders. AWH develops, and markets advanced blood-based diagnostic kits that detect gynecology diseases that focus on risk assessments. AWH’s ovarian cancer test kit is an advanced diagnostic tool that helps doctors and patients make sensible medical decisions and evaluate treatment options. Nicole explains to viewers that ovarian cancer is hard to determine, and once diagnosed, unfortunately, the cancer is sometimes at stages 3 or 4, with about a 30% survival rate. The OvaWatch ^SM kit, launched in 2022, is an ovarian mass monitoring and management test. The Company is advancing the OvaWatch test, awaiting clinical results to be published; upon a successful outcome, this test can assist further in monitoring patients diagnosed with an adnexal mass. Dr. Phan talks about endometriosis and the ongoing development of the Company’s EndoCheck™ test kit. Endometriosis affects millions of women globally, and a non-invasive diagnostic tool can assist patients in forecasting and managing the disease. Drugs are available to help control endometriosis, but they are expensive, and a patient needs to prove a positive endometriosis diagnosis to get the drugs. Painful medical procedures are the only way to confirm a diagnosis of endometriosis. Once available, the EndoCheck™ test kit can become a more beneficial tool for an endometriosis diagnosis. Nicole and Ryan dedicate themselves to helping women with ovarian cancer and other gynecologic disorders. The on-screen QR code is available during the show to download more info or visit Aspira Women’s Health – https://aspirawh.com/ .

Tonight, from the Nasdaq MarketSite , Andy Ross, Chairman/CEO of America Rebel Holdings, Inc. (NASDAQ: AREB) ($AREB) is with New to The Street’s TV Host Jane King with his corporate update. Consumers are recognizing American Rebel’s products as “America’s Patriotic Brand,” as demand continues to grow. The Company has a product line of gun safes, weapon lockers, concealed-carry weapons (CCW) apparel, backpacks, and other products all “Made in America.” The Company’s flagship safe product lines are gaining popularity as affordable, safe, and secure quality products. Consumers can expect a new line of value safes priced between $599-$1499. Andy tells viewers that AREB had great success being an exhibitor at the SHOT Trade Show in January 2023 and at the NRA Trade Show in April, 2023 . Many new dealers have signed with the Company to sell their line of patriotic products. The American Rebel brand is the power of the Company’s marketing and sales. Management is always looking for new and exciting product lines to be part of their “American’s Patriotic Brand.” Andy talks about how demands on certain products are up due to consumers’ concerns about the overall social and economic conditions of America. During the Show, Andy announces his new music CD, “I Stand for You” , a song about the American Flag; the song plays during the interview. Viewers can learn more about the Company’s mission and products through its strong social media presence, websites, and websites like www.americanrebel.com and www.andyross.com . The on-screen QR code is available during the show; download or visit America Rebel, Inc. – http://www.americanrebel.com/ .

Tonight, Blue Castle Ventures, Ltd.’s (CRYPTO: BCVD) ($BCVD) (“Blue Castle”) Chief Executive Officer / Founder David Rojas talks with New to The Street’s TV Host Jane King. The Company is an investor marketplace platform which enables investors to earn points using asset-backed financial blockchain products . David updates viewers that Blue Castle is always innovating to create new financial products that are more competitive than the legacy financial products in the market. The mortgage product is still in development with the expectation of offering a unique blockchain mortgage solution when it becomes available. The Latin American communities in the USA are a target market for the Company’s financial offerings; with a growing and young demographic, the Company’s solutions are gaining in popularity. Blue Castle offers a training course designed to teach those who have no knowledge of stock market mechanics. David explains that competitor courses are trying constantly to have a student buy their financial service offerings. The Blue Castle courses are for anyone to learn without a hard sales push motive. Course graduates can receive 100% of the tuition back plus an additional $200 to start trading on the Blue Castle platform. The Company continues to grow and is looking for talented stock market traders, even those who successfully completed Blue Castle’s course. David sees stock market opportunities in the “Small Cap” sectors and most recently in the AI (Artificial Intelligence) industry. On July 7, 2023, Blue Castle is sponsoring an Artist featuring her creations at the Rockefeller Center in New York. Blue Castle Ventures, Ltd. does not trade cryptocurrencies nor carry out transactions or investments with cryptocurrencies. All the Company’s operations are in US dollars. The Company’s blockchain, $BCVD, is a cryptography and security system. The on-screen QR code is available during the show; download or visit Blue Castle Ventures, Ltd. – https://bluecastleventures.ca/ .

Tonight, Richard T. Schumacher, President/CEO of Pressure BioSciences, Inc. (OTCQB: PBIO) ($PBIO), sits with New to The Street’s TV Host Jane King at the Nasdaq MarketSite to discuss the Company. Pressure BioSciences, Inc. develops and sells innovative extreme pressure-based platform technology solutions for the global life sciences industry. The Company generates revenues from its patented platforms: Pressure Cycling Technology (“PCT™”), BaroFold™ Platform, and Ultra Shear Technology (“UltraShear™” or “UST™”). Combining high-pressure and high shearing, Management and its scientific team created a new era of delivering oil-based nutrients and therapeutics. Richard tells viewers that about 44% of all new pharmaceuticals are from oil-based derivatives. The human body has difficulty absorbing oil molecules, so the Company’s Ultra Shear technology platform can make oil molecules smaller and more absorbent. The Ultra Shear Platform can increase the efficacies of cosmetics, vitamins, drugs, and other health products with higher molecular absorptions. You often buy a product or get a drug from a pharmacist with instructions stating “Shake” before using. PBIO’s creates invisibly solubilized nanoemulsions particles of oil in water that remain mixed, requiring no shaking. The Company recently partnered with CBD Supply MD, a larger supplier of CBD products in the multi-state mid-Atlantic region. Using PBIO technological platform, CBD Supply announced the commercial introduction and availability of their “NanoBloom CBD” Topical Spray. The all-natural CBD Topical Spray delivers rock-solid multi-year stability and is a leap forward in best-in-class, super-fast acting, and highly bioavailable hemp-derived product. The Company has 39 patents, and Management is looking into non-dilutive financing through license agreements on its patents. Richard expects to close on more contracts and sees strong growth for the Company’s UltraShear and other products . The on-screen QR code is available during the show; download or visit Pressure BioSciences, Inc. – https://www.pressurebiosciences.com/ .

New to The Street tonight airs its “Sekur Privacy & Sekur Security Segment – The Weekly Hack .” Alain Ghiai, an internationally acclaimed internet privacy expert and the CEO of Sekur Private Data, Ltd . (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ( Sekur® ), talks with TV Host and Multi-media Journalist Ana Berry about a 2022 Q4 report about Australia being the largest hacked country in the world. Australia was a “Mad-Hacking” target, probably due to geopolitical issues with China. Alain states that the US is perhaps the most hacked nation in the world, with reports saying that about 9.7 billion accounts were hacked. Even though the US population is about 300 million, many in the US have multiple devices and email accounts which explains the billions of hacks in the US. A Virtual Private Network (VPN) is an excellent strategy to help prevent hacking. A VPN encrypts your internet traffic and hides IP address connections. Unfortunately, some VPN providers track your internet traffic and sell that data. The best solution is SekurVPN, a new product launched by Sekur in April 2023, hosted in Switzerland on the Company’s private servers. With a Swiss VPN IP address and military encryption, end-user can virtually eliminate their internet tracks. Sekur never asks for phone numbers or other information, so when you log onto the SekurVPN, you are invisible to those trying to steal your data. Sekur is offering PROMO CODE: PRIVACY which gives a 15% discount on all Sekur services , and if you subscribe for 1 year of services, a subscriber gets another 17% discount. Remember: Sekur never sells data, asks for phone numbers, has no 3 ^rd party cloud applications, and never tracks web traffic, and it operates in Switzerland , a country with some of the strictest privacy laws in the world. The on-screen QR code is available during the show to download more info or visit Sekur Private Data, Ltd. – https://www.sekurprivatedata.com/ , http://www.Sekur.com , and https://www.sekurvpn.com/ . “Privacy Has Arrived.”

About Aspira Women’s Health, Inc. (NASDAQ: AWH) ($AWH):

Aspira Women’s Health, Inc. (NASDAQ: AWH) ($AWH) is transforming women’s gynecological health by discovering, developing, and commercializing innovative testing options for women of all races and ethnicities. Ova1Plus ^® combines our FDA-cleared products, Ova1 ^® and OVERA ^® , to detect the risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck™, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development – www.aspirawh.com .

About American Rebel Holdings, Inc. (NASDAQ: AREB) ($AREB):

American Rebel Holdings, Inc. (NASDAQ: AREB) ($AREB) operates primarily as a designer, manufacturer and marketer of branded safes and personal security and self-defense products. The Company also designs and produces branded apparel and accessories – www.americanrebel.com & www.americanrebel.com/investor-relations .

About Blue Castle Ventures, Ltd. (CRYPTO: BCVD) ($BCVD):

Blue Castle Ventures, Ltd. (CRYPTO: BCVD) ($BCVD) has a priority to provide its clients in Canada and several countries globally the opportunity to access global markets with actively managed strategies that take advantage of the latest asset trends. The Company aims to level the playing field by bringing the same advantages and opportunities that high-net-worth individuals have to retail investors and reducing their exposure to the volatility and potential losses that lack of knowledge of modern trends can cause. For four years, Blue Castle Ventures Ltd. have successfully designed strategies for momentum trading in stocks to the point that the Company grew almost three times during the pandemic, which has now allowed a debut in the digital assets’ world. Blue Castle Ventures launched its own blockchain system capable of exchanging a Point Program, “Blue Castle Ventures Dollar” or “BCVD,” and the bartering of “Digital Art” directly to USD dollars- https://bluecastleventures.ca/ .

About Pressure BioSciences, Inc. (OTCQB: PBIO) ($PBIO):

Pressure BioSciences, Inc. (OTCQB: PBIO) ($PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. The Company’s products utilize both constant and alternating pressure. Its patented Pressure Cycling Technology (PCT) utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. PBIO recently expanded its market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. The Company also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Management’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers – https://www.pressurebiosciences.com/ .

About Sekur Private Data Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0):

Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) is a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management. The Company distributes a suite of secure cloud-based storage, disaster recovery, document management, encrypted emails, and secure communication tools. It sells its products through its websites www.sekur.com , approved distributors, and telecommunication companies worldwide. Sekur Private Data, Ltd. serves consumers, businesses, and governments worldwide – https://www.sekurprivatedata.com and https://www.sekur.com ; Twitter: @sekurprivate .

About New to The Street :

New to the Street is an FMW Media production that operates one of the longest-running US and International sponsored and syndicated Nielsen Rated programming television brands, “New to The Street,” and its blockchain show, “Exploring The Block.” Since 2009, these brands have run biographical interview segment shows across major U.S. television networks. The paid-for-television programming platforms can potentially reach millions of homes in the US and international markets. FMW’s New to The Street / Newsmax televised broadcasting platform airs its syndication on Saturdays at 3:30 – 4:00 PM ET. FMW is also one of the nation’s largest buyers of linear television, long and short-form paid programming – https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/ .

Forward-Looking Statements Disclaimer US/Canada:

This press release contains forward-looking statements within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. Forward-looking statements do not guarantee future performance or results and will not necessarily be accurate indications of the times at which such performance or results are achieved. This press release should be considered in all filings of the Companies contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov .

This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. These statements reflect management’s current beliefs and are based on information currently available to management as of the date hereof. Forward-looking information in this press release includes, without limiting the foregoing, expectations regarding agents that join Real.

CONTACT:

Additional Focus Groups Corroborate UltraShear Nano-THC Produces Equal to Much Better THC Experiences, Even from Lower THC Dosing Levels; Also, Lightning-Fast Pain Relief from Topical Use.

SOUTH EASTON, MA / ACCESSWIRE / May 9, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or “Company”) today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks. The THC Nanoemulsion Oral Spray was prepared using PBI’s revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI’s California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products.

Additional consumer focus group testing more than doubled the original cohort of participants and has strongly affirmed multiple pivotal results on the UltraShear processed Nano-THC Oral Spray being powerfully differentiated from traditional THC dosing alternatives:

1. Speedy onset of first effects (average well under ten minutes – many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes.
2. Much faster progression to maximum effects (average well under 40 minutes – many reports in 30 minutes or less) versus typical THC edibles requiring 60-120 minutes.
3. Eliminates health issues associated with smoking or vaping.
4. Enormous efficiency improvement in dose payload delivery allows equal to much better/greater THC experience from dosing down to a small fraction of user’s normal dosing levels.
5. Stable, all plant formulation is sterile packaged with no added preservatives.
6. Multiple testers applied even a single spray to painful body areas and reported fast to instant transdermal pain relief.

Mr. John B. Hollister, PBIO’s Director of Sales and Marketing, discussed highlights from the studies: “Most testing participants used lower doses of UltraShear Nano-THC than their usual dose level for THC products – and the vast majority of volunteers reported the same, more, or much more effect from the lower dosing of Nano-THC versus their normal dosing choices. Multiple normally heavy users of THC and many other participants reported onset of effects from the Nano-THC Oral Spray very quickly, even at significantly lower THC concentrations than usually consumed.”

Mr. Hollister continued: “Following completion of the oral spray studies, we were also delighted by unplanned outcomes from multiple participants spraying the Nano-THC onto bodily pain locations (joint, arthritis, soreness, etc.) – and reporting very rapid, nearly instant relief from localized pain. All of these reported results are unsurprising to us, as scientific literature has long documented the greatly increased bioavailability of water-insoluble valuable constituents when dissolved into sufficiently small (under 100 nm) oil droplets. PBI’s UltraShear platform accomplishes this with unmatched uniformity, tunable droplet size control, lower cost of production, better ease-of-use, and long-term stability.”

Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: “These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market. We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential explosive adoption of UltraShear processed Nano-THC.”

Mr. Schumacher continued: “We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage, and more. 2023 is poised to be a watershed transformational year for PBI, as we capitalize for roll-out of the UltraShear platform and converge upon our announced NASDAQ or NYSE uplisting goal.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilizeboth constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.